Publications by authors named "Jean Tardu"

Claim this Profile
C
Cost-Effectiveness of Empagliflozin (JARDIANCE) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial.
Harinala Groyer, Romain Supiot, Jean Tardu, Nicolas Virely, Marine Sivignon

Clin Drug Investig· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exit interviews from two randomised placebo-controlled phase 3 studies with caregivers of young children with autism spectrum disorder.
Natalia Hawken, Bruno Falissard, Carl Choquet, Clement Francois, Jean Tardu

Front Child Adolesc Psychiatry· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial.
Laurent Fauchier, Nicolas Lamblin, Jean Tardu, Lucile Bellier, Harinala Groyer

Pharmacoecon Open· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Jean Tardu

PLoS One· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Aurélie Millier, Jean Tardu

J Mark Access Health Policy· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis